# US 2024/0189410 A1 · Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189410 A1
- Document ID: US20240189410A1
- Status: Published application
- Kind: A1
- Application number: 18/535,116
- Filed: 2023-12-11
- Published: 2024-06-13
- Earliest claimed: 2022-12-13
- Assignees: Pfizer Inc.
- Applicants: Pfizer Inc.
- Inventors: Annaliesa Sybil Anderson; Marina A. Gonzalez-Garis; Lei Hu; Isis Kanevsky; Paul Arthur Liberator; Justin Keith Moran; Lynn Marie Phelan; Michael William Pride; Shuai Shi; Naveen Surendran
- Web page: https://patentgrep.com/patent/US20240189410A1

## CPC

- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/04: Antibacterial agents
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.

## Claims

### Claim 1

A immunogenic composition comprising a Clostridioides difficile (C. difficile) toxoid A and/or toxoid B, and a CpG adjuvant comprising at least one CpG or a saponin containing liposomal adjuvant.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant comprises a B class CpG.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant comprises CpG 24555 (SEQ ID NO: 48).

### Claim 5 (depends on 1)

The immunogenic composition of claim 1, comprising about 0.1 to 5 mg/mL or higher, about 0.1 to about 1.0 mg/mL, about 0.5 to about 1.5 mg/mL, about 0.8 to about 1.8 mg/mL, or about 3.0 to about 4.0 mg/mL CpG.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, comprising about 0.5 mg/mL, about 1.0 mg/mL, about 1.2 mg/mL, or about 3.6 mg/mL CpG.

### Claim 7 (depends on 1)

The immunogenic composition of claim 1, comprising about 3.6 mg/mL CpG.

### Claim 8 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant further comprises an additional adjuvant.

### Claim 9 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant further comprises an aluminum salt selected from aluminum phosphate, aluminum sulfate and aluminum hydroxide (Al(OH)3).

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The immunogenic composition of claim 1, comprising a CpG and about 0.1 to 5 mg/mL, about 0.5 to about 1.5 mg/mL, or about 1.0 to about 2.5 mg/mL Al(OH)3.

### Claim 12 (depends on 1)

The immunogenic composition of claim 1, comprising a CpG and about 1.0, about 1.5, about 1.7, about 1.8, about 2.0, or about 2.5 Al(OH)3.

### Claim 13 (depends on 1)

The immunogenic composition of claim 1, comprising about 0.5 to about 3.6 mg/mL CpG and about 0.1 to 5 mg/mL Al(OH)3.

### Claim 14 (depends on 1)

The immunogenic composition of claim 1, comprising:
about 1.0 mg/mL CpG and about 1.5 mg/mL Al(OH)3;
about 1.2, 1.3, 1.4, 1.5, or 1.6 mg/mL CpG and about 1.7 mg/mL Al(OH)3;
about 1.5, 1.6, 1.7, 1.8, or 1.9 mg/mL CpG and about 2.0 mg/mL Al(OH)3;
about 1.8, 1.9, 2.0, 2.1, 2.2, or 2.4 mg/mL CpG and about 2.5 mg/mL Al(OH)3;
about 3.6 mg/mL CpG and about 1.8 mg/mL Al(OH)3;
about 1.4 mg/mL CpG and about 1.7 mg/mL or higher Al(OH)3;
about 1.6 mg/mL CpG and about 2.0 mg/mL or higher Al(OH)3; or
about 2.0 mg/mL CpG and about 2.5 mg/mL or higher Al(OH)3.

### Claim 15 (depends on 1)

The immunogenic composition of claim 1,
comprising a mass ratio of CpG/Al(OH)3 of about 1.21 or higher.

### Claim 16 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant comprises a histidine or phosphate buffer.

### Claim 17 (depends on 16)

The immunogenic composition of claim 16, wherein the histidine or phosphate buffer is at a concentration of about 5 mM to 15 mM, or preferably about 10 mM.

### Claim 18 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant comprises sodium chloride.

### Claim 19 (depends on 18)

The immunogenic composition of claim 18, wherein the sodium chloride is at a concentration of about 20 mM to 100 mM, or preferably about 50 mM or about 60 mM.

### Claim 20 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant has a pH of about 6.0 to 7.0, or preferably about 6.5.

### Claim 21 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant comprises about 3.6 mg/mL CpG 24555.

### Claim 22 (depends on 1)

The immunogenic composition of claim 1, wherein the CpG adjuvant comprises about 1.0 mg/mL CpG 24555 and about 1.5 mg/mL of Al(OH)3.

### Claim 23 (depends on 1)

The immunogenic composition of claim 1, wherein the saponin containing liposomal adjuvant comprises a saponin and a monophosphoryl lipid A (MPLA)-containing liposome composition, wherein the liposome composition comprises i) a lipid bilayer comprising phospholipids and ii) cholesterol.

### Claim 24 (depends on 23)

The immunogenic composition of claim 23, wherein the saponin is selected from QS-7, QS-18, QS-21, or a mixture thereof.

### Claim 25

(canceled)

### Claim 26 (depends on 23)

The immunogenic composition of claim 23, wherein the phospholipid is selected from dimyristoyl phosphatidylcholine (DMPC), dipalmitoyl phosphatidylcholine (DPPC), distearyl phosphatidylcholine (DSPC), dimyristoyl phosphatidylglycerol (DMPG), dipalmitoyl phosphatidylglycerol (DPPG), and distearyl phosphatidylglycerol (DSPG).

### Claim 27

(canceled)

### Claim 28 (depends on 1)

The immunogenic composition of claim 1, wherein the saponin containing liposomal adjuvant comprises QS-21, Monophosphoryl Lipid A (MPLA), DMPC, DMPG and cholesterol.

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The immunogenic composition of claim 1, comprising:
about 0.1 to about 0.4 mg/mL of QS-21, preferably about 0.2 mg/mL of QS-21;
about 0.2 to about 0.6 mg/mL of MPLA, preferably about 0.4 mg/mL of MPLA;
about 5 to about 15 mg/mL of cholesterol, preferably about 11 mg/mL of cholesterol;
about 5 to about 20 mg/mL of DMPC, preferably about 14 mg/mL of DMPC; and/or
about 1.0 to about 2.0 mg/mL of DMPG, preferably about 1.6 mg/mL of DMPG.

### Claim 31 (depends on 1)

The immunogenic composition of claim 1, wherein the saponin containing liposomal adjuvant comprises a histidine or phosphate buffer.

### Claim 32 (depends on 31)

The immunogenic composition of claim 31, wherein the phosphate buffer is at a concentration of about 5 mM to 15 mM, or preferably about 10 mM, and optionally, further comprises sodium chloride at a concentration of about 100 mM to 200 mM, or preferably about 150 mM.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The immunogenic composition of claim 1, wherein the saponin containing liposomal adjuvant has a pH of about 5.5 to 7.0, preferably about 6.2.

### Claim 35 (depends on 1)

The immunogenic composition of claim 1, wherein the C. difficile toxoid A comprises the amino acid sequence of SEQ ID NO: 4, wherein the initial methionine is absent, and C. difficile toxoid B comprises the amino acid sequence of SEQ ID NO: 6, wherein the initial methionine is absent.

### Claim 36 (depends on 1)

The immunogenic composition of claim 1, wherein the C. difficile toxoid A comprises the amino acid sequence of SEQ ID NO: 84, and C. difficile toxoid B comprises the amino acid sequence of SEQ ID NO: 86.

### Claim 37 (depends on 1)

The immunogenic composition of claim 1, wherein the composition comprises the C. difficile toxoid A and the C. difficile toxoid B in a ratio of about 3:1 to about 1:1 and/or the composition comprises 200 ρq of toxoid per dose.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The immunogenic composition of claim 1, wherein the C. difficile toxoid A and toxoid B are lyophilized and reconstituted with a CpG adjuvant or a saponin containing liposomal adjuvant.

### Claim 40 (depends on 39)

The immunogenic composition of claim 39, wherein the lyophilized C. difficile toxoid A and toxoid B are reconstituted with:
a CpG adjuvant comprising about 3.6 mg/mL CpG 24555,
a CpG adjuvant comprising about 1.0 mg/mL CpG 24555 and about 1.5 mq/mL Al(OH)3; and/or
a saponin containing liposomal adjuvant comprising about 0.2 mq/mL QS-21, about 0.4 mg/mL Monophosphoryl 3-Deacyl Lipid A, about 14 mq/mL DMPC, about 1.6 mq/mL DMPG and about 11 mq/mL cholesterol.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The immunogenic composition of claim 1, wherein the composition is administered at a dose volume of 0.5 mL.

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46 (depends on 1)

A method of eliciting an immune response in a human subject against C. difficile, the method comprising administering to the human subject an immunogenic composition of claim 1.

### Claim 47 (depends on 1)

A method of preventing, treating or ameliorating an infection, disease or condition associated with C. difficile in a human subject, the method comprising administering to the human subject an immunogenic composition of claim 1.

### Claim 48 (depends on 1)

A method of preventing, treating or ameliorating a medically attended C. difficile infection in a human subject, the method comprising administering to the human subject an immunogenic composition of claim 1.

### Claim 49 (depends on 46)

The method of claim 46, wherein the immunogenic composition is administered in a first and second dose.

### Claim 50 (depends on 49)

The method of claim 49, wherein the second dose is administered about 2 months after the first dose (e.g. M 0, 2) or about 6 months after the first dose (M 0, 6).

### Claim 51 (depends on 46)

The method of claim 46, wherein the human subject is 18 years of age or older, 50 years of age or older, 55 years of age or older, 60 years of age or older, 65 years of age or older, or 70 years of age or older.

### Claim 52 (depends on 46)

The method of claim 46, wherein
the immune response elicits neutralizing antibodies against C. difficile toxin A and/or neutralizing antibodies against C. difficile toxin B; and/or
the immune response elicits greater neutralizing antibodies against C. difficile toxin A and/or B after administration of 2 doses of the immunogenic composition compared to administration of 3 doses of the investigational C. difficile vaccine.

### Claim 53

(canceled)
